Evidence map›Paper›PMID 42436119›Full record

ArticleNature communications2026

Colorectal cancer co-opts an epidermal wound healing program during metastasis to generate disseminated tumor cells.

Mizuho Sakahara, Takuya Okamoto, Kohei Kumegawa, Yasuko Natsume, Daisuke Kusama, Hitomi Yamanaka, Rie Komatsuzaki, Katsuyuki Yaginuma, Upasna Srivastava, Atsushi Takahashi-Kanemitsu and 5 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mizuho Sakahara *Department of Cell Biology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Takuya Okamoto *Department of Cell Biology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Kohei KumegawaCancer Cell Diversity Project, NEXT-Ganken Program, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID http://orcid.org/0000-0003-3732-2874
Yasuko NatsumeDepartment of Cell Biology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Daisuke KusamaDepartment of Cell Biology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Hitomi YamanakaDepartment of Cell Biology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Rie KomatsuzakiDepartment of Cell Biology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Katsuyuki YaginumaDepartment of Cell Biology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Upasna SrivastavaDepartment of Neurology, Yale School of Medicine, Yale University, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-4096-9257
Atsushi Takahashi-KanemitsuDepartment of Biochemistry & Systems Biomedicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0002-4156-9522
Etsuo A SusakiDepartment of Biochemistry & Systems Biomedicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Kazutaka ObamaDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Satoshi NagayamaDepartment of Surgery, Uji-Tokushukai Medical Center, Uji, Kyoto, Japan.ORCID http://orcid.org/0000-0001-9632-914X
Reo MaruyamaCancer Cell Diversity Project, NEXT-Ganken Program, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID http://orcid.org/0000-0001-7166-5964
Ryoji YaoDepartment of Cell Biology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. ryao@jfcr.or.jp.ORCID http://orcid.org/0000-0003-0327-0965

Funding

Japan Agency for Medical Research and Development (AMED) JP23ama221116Japan Agency for Medical Research and Development (AMED) JP24ama221141Japan Agency for Medical Research and Development (AMED) JP25ama221610MEXT | Japan Science and Technology Agency (JST) 21H02770MEXT | Japan Science and Technology Agency (JST) 22K19468MEXT | Japan Science and Technology Agency (JST) 24K02311MEXT | Japan Science and Technology Agency (JST) 24K22075
6 · The paper itself

Abstract

Metastasis is the principal cause of death from colorectal cancer (CRC), yet the cellular states that enable tumor dissemination remain poorly defined. Disseminated tumor cells (DTCs) are rare, transient, and clinically inaccessible, limiting mechanistic insight into their biology. Here we show that CRC cells transiently adopt a wound-healing program normally used by epidermal keratinocytes during tissue repair to enable metastatic dissemination. Using serial orthotopic transplantation of patient-derived organoids to model metastasis, we find that DTCs lose cancer stem cell features and instead express wound-inducible keratins, including KRT17, before metastatic outgrowth. This state is reversible, as cells reacquire primary tumor-like characteristics upon colonization of distant organs. Mechanistically, this transition is associated with reduced EZH2 activity and activation of YAP signaling. Clinically, KRT17⁺ cells localize to the invasive front of primary CRCs and are absent from adjacent normal tissue. These findings uncover unexpected lineage plasticity across distinct developmental origins and identify a transient, targetable state critical for metastatic progression.

Indexed as

Colorectal NeoplasmsEpidermisWound HealingAdaptor Proteins, Signal TransducingAnimalsCell Line, TumorEnhancer of Zeste Homolog 2 ProteinFemaleHumansKeratin-17KeratinocytesMiceNeoplasm MetastasisNeoplastic Stem CellsPhosphoproteinsSignal TransductionAdaptor Proteins, Signal TransducingEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanKeratin-17PhosphoproteinsTranscription FactorsYAP-Signaling Proteins

Identifiers

PMID42436119
PMCPMC13487178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.